BRIEF-Corbus Pharma's inflammatory disease drug succeeds mid-stage study
October 19, 2017 at 11:23 AM EDT
* Corbus Pharmaceuticals reports positive topline results from phase 2 study in rare autoimmune disease dermatomyositis
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.